Get started

Financials · ABCL

AbCellera Biologics Inc. (ABCL) financials

For the twelve months ended Jun 30, 2026, AbCellera Biologics Inc. reported $66.17M of revenue and -$164.66M of net income.

Revenue, TTM
$66.17M
Revenue growth, YoY
+101.3%
Net income, TTM
-$164.66M
Net margin
-248.8%
Free cash flow, TTM
-$119.67M
EPS, diluted, TTM
-$0.54
Cash
$120.06M
P/S
61.19
Market cap
$4.05B
Annual revenue$75.13M
FY2019FY2025
Annual net income-$146.41M
FY2019FY2025
Annual free cash flow-$174.07M
FY2019FY2025

ABCL revenue and earnings growth

ABCL revenueQ2 2026$4.05M

Quarter YoY
-76.3%
QoQ
-51.3%
FY YoY
+160.6%
5Y CAGR
-20.3%

ABCL revenue was $4.05M in fiscal Q2 2026 (ended Jun 30, 2026), down 76.3% from a year earlier and down 51.3% from the prior quarter. For the full fiscal 2025 it was $75.13M, up 160.6% from fiscal 2024. Compound annual growth was -20.3% over 5 years. It rose in 4 of the last 6 fiscal years.

ABCL net incomeQ2 2026-$55.43M

ABCL net income was -$55.43M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$34.73M a year earlier. For the full fiscal 2025 it was -$146.41M, compared with -$162.86M in fiscal 2024.

ABCL EPSQ2 2026-$0.18

ABCL diluted EPS was -$0.18 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.12 a year earlier. For the full fiscal 2025 it was -$0.49, compared with -$0.55 in fiscal 2024.

ABCL free cash flowQ2 2026$23.79M

ABCL free cash flow was $23.79M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$45.77M a year earlier. For the full fiscal 2025 it was -$174.07M, compared with -$186.95M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue$75.13M$28.83M$38.02M$485.42M$375.20M$233.16M$11.61M
Research and development$186.83M$167.26M$175.66M$107.88M$62.06M$29.39M$10.11M
Selling, general and admin$83.23M$85.49M$75.18M$55.48M$41.85M$11.91M$2.75M
Operating income-$217.10M-$314.77M-$237.21M$216.51M$204.41M$156.03M-$4.12M
Pre-tax income-$177.59M-$200.40M-$174.03M$239.10M$219.15M$157.83M-$2.21M
Income tax-$31.18M-$37.54M-$27.63M$80.58M$65.69M$38.91M-
Net income-$146.41M-$162.86M-$146.40M$158.52M$153.46M$118.92M-$2.21M
EPS, basic-$0.49-$0.55-$0.51$0.56$0.56$0.53-$0.01
EPS, diluted-$0.49-$0.55-$0.51$0.50$0.48$0.45-$0.01
Diluted shares298.7M294.3M289.2M314.8M318.3M263.1M151.3M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Cash and equivalents$128.51M$156.32M$158.32M$411.54M$501.14M$594.12M-
Receivables$39.41M$31.98M$0--$903.0K-
Inventory$6.34M$0-----
Current assets$728.23M$751.37M$871.99M$1.03B$929.80M$813.33M-
Goodwill$47.81M$47.81M$47.81M$47.81M$47.81M$31.50M-
Total assets$1.36B$1.36B$1.49B$1.54B$1.32B$1.01B-
Current liabilities$64.31M$76.61M$119.01M$118.32M$120.68M$103.49M-
Short-term debt-----$190.0K-
Total liabilities$390.05M$304.47M$335.78M$307.63M$292.84M$175.03M-
Shareholders' equity$966.90M$1.06B$1.15B$1.23B$1.03B$830.51M$10.25M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Operating cash flow-$131.29M-$108.56M-$43.88M$277.36M$244.58M$22.69M$2.69M
Capital expenditures$42.77M$78.40M$76.95M$70.66M$58.45M$9.67M$4.00M
Free cash flow-$174.07M-$186.95M-$120.82M$206.70M$186.13M$13.02M-$1.30M
Investing cash flow$87.75M$121.41M-$221.11M-$352.63M-$332.25M-$119.78M-$5.78M
Financing cash flow$14.08M$12.77M$10.36M-$1.63M-$3.89M$683.65M$195.0K
Stock-based compensation$55.79M$67.58M$64.18M$49.48M$30.65M$8.40M$890.0K
Depreciation and amortization--$24.39M$27.84M$14.45M$4.84M$1.60M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue growth, YoY160.6%-24.2%-92.2%29.4%60.9%1907.9%-
Net income growth, YoY---3.3%29.1%--
EPS growth, YoY---4.2%6.7%--
Operating margin-289.0%-1091.7%-623.8%44.6%54.5%66.9%-35.5%
Net margin-194.9%-564.8%-385.0%32.7%40.9%51.0%-19.0%
Free cash flow margin-231.7%-648.4%-317.7%42.6%49.6%5.6%-11.2%
Return on equity-15.1%-15.4%-12.7%12.9%15.0%14.3%-21.6%
Return on assets-10.8%-12.0%-9.8%10.3%11.6%11.8%-
Current ratio11.329.817.338.677.707.86-

Source: XBRL data AbCellera Biologics Inc. files with the SEC, latest filing dated Aug 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ABCL peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ABCL$66.17M+101.3%-$164.66M-248.8%$4.05B
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

ABCL FAQ

8 questions
  • What is ABCL revenue?
    AbCellera Biologics Inc. (ABCL) reported $66.17M of revenue for the twelve months ended Jun 30, 2026. That is up 101.3% from the year before. Revenue for fiscal 2025 was $75.13M.
  • Is ABCL profitable?
    No. AbCellera Biologics Inc. reported a net loss of $164.66M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does ABCL have?
    AbCellera Biologics Inc. reported $120.06M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is ABCL revenue growing?
    AbCellera Biologics Inc.'s revenue changed +160.6% in fiscal 2025, to $75.13M. Its compound annual growth rate was -20.3% over 5 years.
  • What is ABCL free cash flow?
    AbCellera Biologics Inc. generated -$119.67M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$94.94M less capital expenditures.
  • What is ABCL earnings per share?
    Diluted earnings per share were -$0.54 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did ABCL last report financial results?
    The latest statements here come from AbCellera Biologics Inc.'s 10-Q filed on Aug 5, 2026, covering the period ended Jun 30, 2026.
  • Where does this ABCL financial data come from?
    Quantisnow builds these statements from the structured XBRL data AbCellera Biologics Inc. files with the SEC. It is provided for information only and is not investment advice.